respiratory therapy schools
ATHENS, Ohio — Diagnostic Hybrids, a leading developer of in vitro diagnostic
fluorescent staining kits and cell culture products, announces the U.S.
Food and Drug Administration (FDA) (510k) clearance of its D3
FastPointTM L-DFATM RSV/MPV Identification
Kit, which allows for the identification of respiratory syncytial virus
and human metapneumovirus from a patient’s specimen in under 25 minutes.
The D3 FastPoint L-DFA RSV/MPV ID Kit represents the third
product in the company’s D3 FastPoint L-DFA product line, and
its second cleared MPV testing device. The kit is also the only
FDA-cleared product that can be used to detect both RSV and hMPV
antigens simultaneously from clinical samples.
D3 FastPoint incorporates the same proprietary and
proven monoclonal antibodies present in Diagnostic Hybrids’ other
respiratory virus products. The kit uses the fluorescent labeling
technologies of the company’s D3 UltraTM
and D3 DuetTM product lines in combination with
newly developed L-DFA processing technology to create a unique rapid
testing format. The new patent-pending L-DFA technology also allows for
the simultaneous identification of two respiratory viruses in a single
slide well. The D3 FastPoint L-DFA RSV/MPV Identification Kit
will allow laboratories to identify respiratory syncytial virus and
metapneumovirus infections in the same timeframe as currently available
point-of-care rapid antigen tests, which generally do not include MPV
testing options. RSV is the leading cause of infectious viral disease in
infants and children under the age of 1 and can be severe in patients
with cardiac anomalies1. Human metapneumovirus causes
significant disease in all age groups, but particularly in children and
elderly adults2.
“The D3 FastPoint L-DFA RSV/MPV Identification Kit provides
any laboratory receiving and processing samples from pediatric or
geriatric patients with a means to rapidly and accurately detect and
identify two of the most significant respiratory viruses for those
patient populations,” said Steve Ewers, Senior Product Manager at
Diagnostic Hybrids. “This sensitive, accurate result in less than 25
minutes can support the diagnostic algorithm in a clinically relevant
timeframe,” Ewers added.
“This new product is an excellent complement to our D3
FastPoint portfolio of rapid testing products,” said David R. Scholl,
Ph.D., President CEO of Diagnostic Hybrids. “With the D3
FastPoint RSV/MPV kit, we are able to provide improved rapid respiratory
testing solutions to laboratories focused on respiratory syncytial virus
and metapneumovirus diagnosis for pediatric and geriatric hospitals and
clinics,” Scholl added.
Viruses love plane travel. They get to fly around the world inside a closed container while their infected carrier breathes and coughs, spreading pathogens to other passengers, either by direct contact or through the air. And once people deplane, the virus can spread to other geographical areas. Scientists already know that smallpox, measles, tuberculosis, seasonal influenza and severe acute respiratory syndrome (SARS) can be transmitted during commercial flights. Sally Blower, director of the Center for Biomedical Modeling at the Semel Institute for Neuroscience and Human Behavior at UCLA, along with Bradley Wagner and Brian Coburn, postdoctoral fellows in Blowers research group, used novel mathematical modeling techniques to predict in-flight transmission of the H1N1 virus. They found that transmission could be rather significant, particularly during long flights, if the infected individual travels in economy class. Specifically, two to five infections could occur during a five-hour flight, five to 10 during an 11-hour flight, and seven to 17 during a 17-hour flight.
If you found this page useful, consider linking to it.
Simply copy and paste the code below into your web site (Ctrl+C to copy)
It will look like this: respiratory therapy schools
Leave a Reply